Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate

Area of Science:

• Rheumatology
• Pulmonology
• Clinical Pharmacology

Background:

• Methotrexate is a widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis (RA).
• Short-term studies suggest methotrexate is generally well-tolerated with few serious adverse events.
• Long-term safety data, particularly regarding pulmonary complications, requires ongoing evaluation.

Observation:

• A review of 168 patients on methotrexate for RA identified nine cases of probable or possible methotrexate-induced pulmonary toxicity.
• This indicates a prevalence of 5% and an incidence of 3.9 per 100 patients per year for this adverse event.
• No specific clinical or laboratory features were found to predict the development of pulmonary disease.

Findings:

• Methotrexate-induced pulmonary toxicity is a potential complication in patients with rheumatoid arthritis.
• The observed prevalence and incidence highlight the need for vigilance.
• Early identification and intervention are key, as all reviewed patients recovered fully.

Implications:

• Clinical monitoring for pulmonary complications should be standard practice for all RA patients on long-term methotrexate therapy.
• Further research may elucidate predictive factors for methotrexate-induced pulmonary toxicity.
• This underscores the importance of a comprehensive risk-benefit assessment in RA management.